Neovacs: collaboration contract with INSERM team
The biopharmaceutical company explains that the aim of this one-year agreement is to jointly carry out the proof-of-concept of a new platform using vaccines developed by Neovacs.
It adds that this collaboration contract includes a 24-month option for Neovacs to obtain exclusive worldwide exploitation rights to the results of the joint project.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction